In summary, our findings suggest that p53 mutational status may represent a predictive biomarker for IO efficacy and that an approach combining IO and Chk1 inhibition could represent a potential therapeutic approach for patients with r/r B-ALL expressing mutant p53 that are unlikely to benefit from IO monotherapy. The gene discussed is TP53; the disease is acute lymphoblastic leukemia.